{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:37:01Z","timestamp":1781307421979,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.eplepsyres.2015.06.013","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T23:54:09Z","timestamp":1435017249000},"page":"147-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests"],"prefix":"10.1016","volume":"115","author":[{"given":"M.","family":"Ley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Principe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Jim\u00e9nez-Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rocamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","article-title":"Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment","volume":"64","author":"Almeida","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0010","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0091270004267591","article-title":"Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans","volume":"44","author":"Almeida","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0020","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0025","first-page":"103","article-title":"Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures","volume":"6","author":"Brown","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0035","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(94)92270-5","article-title":"Mortality from epilepsy: results from a prospective population-based study","volume":"344","author":"Cockerell","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eplepsyres.2013.11.022","article-title":"The effects of eslicarbazepine on persistent Na(+) current and the role of the Na(+) channel beta subunits","volume":"108","author":"Doeser","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0045","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/epi.12242","article-title":"Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers","volume":"54","author":"Elger","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/11596290-000000000-00000","article-title":"Pharmacokinetics, drug interactions and exposure\u2013response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses","volume":"26","author":"Falc\u00e3o","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0055","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/bdd.549","article-title":"Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker","volume":"28","author":"Falc\u00e3o","year":"2007","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0060","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.eplepsyres.2013.04.009","article-title":"Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects","volume":"106","author":"Falc\u00e3o","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0065","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/0126839-200809060-00007","article-title":"Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers","volume":"9","author":"Fontes-Ribeiro","year":"2008","journal-title":"Drugs R D"},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0070","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/j.1468-1331.2006.01535.x","article-title":"Preliminary report on effects of oxcarbazepine-treatment on serum lipid levels in children","volume":"13","author":"Franzoni","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0075","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ene.12262","article-title":"Lipid profile and thyroid hormone concentrations in children with epilepsy treated with oxcarbazepine monotherapy: a prospective long-term study","volume":"21","author":"Garoufi","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1528-1167.2012.03605.x","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies","volume":"54","author":"Gil-Nagel","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0085","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0920-1211(01)00231-5","article-title":"Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(\u2212)-10,11-dihydro-10-hydroxy carbamazepine","volume":"44","author":"Hainzl","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CPP46119","article-title":"Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate","volume":"46","author":"Maia","year":"2008","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0095","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.nrl.2013.02.013","article-title":"Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results","volume":"29","author":"Massot","year":"2014","journal-title":"Neurologia"},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0100","first-page":"551","article-title":"[Eslicarbazepine acetate: a novel therapeutic alternative in the treatment of focal seizures]","volume":"54","author":"Mauri-Llerda","year":"2012","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0105","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.yebeh.2010.04.022","article-title":"Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers","volume":"18","author":"Milovan","year":"2010","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0110","first-page":"MT50","article-title":"The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy","volume":"10","author":"Nikolaos","year":"2004","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/088307380001500217","article-title":"Oxcarbazepine versus carbamazepine treatment and induction of serum lipid abnormalities","volume":"15","author":"Papacostas","year":"2000","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0120","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.rce.2014.06.001","article-title":"Atherogenic dyslipidemia: prevalence and management in lipid clinics","volume":"214","author":"Pedro-Botet","year":"2014","journal-title":"Rev. Clin. Esp."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.eplepsyres.2011.05.013","article-title":"Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures","volume":"96","author":"Perucca","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0130","first-page":"309","article-title":"[Eslicarbazepine acetate in clinical practice. Efficacy and safety results]","volume":"56","author":"Serrano-Castro","year":"2013","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0135","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s00115-010-3177-3","article-title":"[Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate]","volume":"82","author":"Steinhoff","year":"2011","journal-title":"Nervenarzt"},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0140","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.eplepsyres.2014.04.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study","volume":"108","author":"Villanueva","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.braindev.2011.05.009","article-title":"Effects of oxcarbazepine treatment on serum lipids and carotid intima media thickness in children","volume":"34","author":"Yi\u015f","year":"2012","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2015.06.013_bib0150","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","article-title":"Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine","volume":"22","author":"Zaccara","year":"2013","journal-title":"Seizure"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121115300188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121115300188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:33:46Z","timestamp":1760276026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121115300188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":30,"alternative-id":["S0920121115300188"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.06.013","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2015.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}